Mr. Giles brings to NOBLE Capital Markets more than 30 years of investment banking and capital markets experience. Most recently Mr. Giles was head of the technology group at Stifel Nicolaus and prior to that spent 16 years at A.G. Edwards as head of its emerging growth group that included both Edwards' technology and healthcare practices. During his career he has executed over 100 public financings raising over $4 billion for his clients, including IPOs for companies such as VMWare, COMPAQ, Cardica and ExecuStay. He also has overseen numerous M&A transactions on the buy side as well as the sell side. Mr. Giles received his AB from Harvard College and his MBA from the Harvard Business School. Mr. Giles holds various FINRA licenses and works out of the company's Boston Office.

Christopher Ensley is a Managing Director of technology, media & telecom (TMT) investment banking at NOBLE Capital Markets where he focuses on capital raising, mergers and acquisition advisory and valuation opinions for clients. During his tenure on Wall Street, Mr. Ensley has participated in over $16B in transactions. Prior to NOBLE, Mr. Ensley was a TMT investment banker at Coady Diemar Partners, a boutique investment bank in NYC. Prior to Coady Diemar, Mr. Ensley was a Managing Director in the equity research department at Bear Stearns. While at Bear Stearns, Mr. Ensley was a member of the #1 rated broadcast equity research team for six straight years (2002-2007). Mr. Ensley was a Vice President of equity research covering the broadcast sector at Lazard. He began his Wall Street career as an equity research analyst at Salomon Brothers where he covered the tower industry in addition to the broadcasting industry. He received an MBA from Vanderbilt University and a BA from the College of William & Mary.

Nathan Cali has more than 14 years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal. Mr Cali is the co-founder of Variant Pharmaceuticals an early stage biotechnology company advancing orphan drugs for the treatment of renal diseases. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization and a member of the Development Board of Palm Beach County. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.

Francisco Penafiel joined NOBLE Capital Markets in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science. Prior to joining the investment banking department at Noble in 2011, Francisco was part of NOBLE's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee. Francisco holds various FINRA licenses and is a candidate in the CFA program.

Mr. Arvelo has more than 18 years of corporate finance and capital markets experience, with a special focus on M&A, restructuring and capital raising transactions. Mr. Arvelo has successfully completed equity placements, MBO’s, restructurings and M&A assignments in USA, Latin America and Africa. Prior to joining NOBLE, Mr. Arvelo worked as Director at Enkeros Investments and Activa Capital Markets, and has been Director (BOD), Financial Advisor and interim officer for various companies, with main focus in the QSR, financial institutions and energy sectors. After finishing his Masters in Finance, Mr. Arvelo joined the corporate finance and recoveries division at PricewaterhouseCoopers (PwC), and was responsible for M&A transactions, Corporate Valuation Consulting Services, Project Finance, Privatizations and Dispute Analysis & Investigations. Mr. Arvelo graduated in Economics from Universidad Catolica Andres Bello (B.A. 1993), holds a Masters in Finance from IESA (M.A. 1997) and also graduated Magna Cum Laude from the MBA program at Babson College, with a majors Entrepreneurship and Strategy (M.B.A. 2004).

Mark Suarez joined Noble Capital Markets as Managing Director leading the marine shipping & surface transportation investment banking practice. For over 12 years, Mark has held senior positions in investment banking and equity research. Most recently, he was a Senior Advisor for McQuilling Holdings, the investment banking arm of McQuilling Partners, focusing on the maritime space. Prior to that, between 2011 and 2015, Mark was Director of Research at Euro Pacific Capital, covering the global transportation & logistics sector. Prior to joining Euro Pacific Capital, Mark was a research analyst at Wolfe Research, covering the railroad and intermodal industries. Mark started his career at CIBC, followed by National Bank Financial (NBF), covering the surface and marine transportation space. He has been frequently quoted on industry publications like Tradewinds, JOC, Globe and Mail and TheStreet. In 2015, Thomson Reuters StarMine Analyst Awards Program named him as the number one ranked sell-side Marine Shipping Analyst in terms of earnings estimation, and number two ranked in terms of stock picking. Mark holds a Masters degree in Economics from the University of Toronto and a Bachelor of Commerce degree in Economics & Finance from McGill University. Mark is also a CFA charterholder and holds FINRA Series 7, 63, 79, 86, 87 and 24 registrations.

Mr. Joseph Hain, also known as Joey, serves as Director of Investment Banking at Noble Capital Markets. Mr. Hain served as Managing Director, Head Trader, and Portfolio Manager at the Lawrence Fund LP, where he oversaw and directed the entire trading and class action lawsuit operation. Mr. Hain is the Co-Founder and Limited Partner at Intrinsic Value Capital LP. Previously, he served as a Portfolio Manager of Robotti & Company, Incorporated, where he managed portfolios of HNW individuals and family businesses as well as served as Portfolio Manager of the Glaubman Rosenberg & Robotti Fund LP. a fundamental value focused hedge fund. Mr. Hain began investment banking in 2008 and served as Senior Vice President at WestPark Capital, Tejas Securities, Wynston Hill Capital Management, and Paulson Investment Company. Mr. Hain was also Senior Vice President at Stern Aegis Ventures an affiliate of Aegis Capital Corp. and worked with both public and private companies as well as institutional, retail and HNW clients globally. Mr. Hain is a recipient of 40 under 40 for M&A and Dealmaking from M & A Advisor, Mr. Hain is on the Advisory Board of the Naomi Berrie Center for Diabetes at Columbia University. Mr. Hain holds the following security designations: Series 7, 63, 65, and 79 FINRA Licenses. Mr. Hain received a Bachelor of Science from the State University of New York at Albany with a core concentration in Biology, Chemistry, and Physics

Guranda has an M.B.A. specializing in Financial Valuation and Investment Management and a B.S. in International Business from Lynn University. She has been part of Noble for a few years working on various proprietary projects and in 2019, she joined the Life Science group in Investment Banking. Previously, Guranda worked as a financial analyst at a Tech startup in New York and Real Estate Investment Analyst in Boca Raton, FL.

Mr. Musing is the former Global Head of Biotechnology Licensing and Business Development and has been responsible for global Drug Licensing at Johnson & Johnson. In that position he negotiated and signed several multi-million dollar deals with medium and large pharmaceutical and biotechnology companies on a worldwide basis. He has more than 36 years' experience in the biotechnology and pharmaceutical industry and has been President and Managing Director of Johnson & Johnson Companies in the US and Europe, President of Ares Serono in the US and Executive Vice President for Ares Serono companies in North and Latin America. Mr. Musing has been on the Board of Johnson & Johnson Companies in Germany, France, Italy and the UK, and has been a Member of the Management Board of Ortho Biotech, (a J&J biotechnology company) in the US and Europe. He is currently Executive Chairman of Pelican Therapeutics and is a member of the Board of several companies including Delphi Digital and TherapeuticsMD.

Michael Lerner, Chair of Lowenstein Sandler's Life Sciences Group, has been advising pharmaceutical, life sciences and healthcare companies on key strategic matters for over 30 years. Previously, he served as VP and General Counsel at Reliant Pharmaceuticals, Inc., helping it grow into one of the nation's largest privately held pharmaceutical companies before it was acquired by GSK in 2007. As part of the senior management team, Mr. Lerner led product acquisitions and dispositions totaling in excess of $650 million, and raised more than $660 million in equity and debt. Mr. Lerner subsequently served as SVP and General Counsel of EKR Therapeutics, a specialty pharmaceutical company. Earlier in his career, Mr. Lerner was at the law firm of Gibbons PC, where he was the partner in charge of the pharmaceutical and life sciences practice. Mr. Lerner currently serves on the Board of Directors of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues, which is part of Rutgers Graduate School of Business.

Josée E. Leysen, 36 years as a Scientist, former member of the Research Management Board and Vice president of Business Development at Janssen Pharmaceutica, Belgium, a Johnson & Johnson company. In 1999 she became a Business Development Executive in Scientific Licensing, where she was responsible for identification and evaluation of licensing and collaboration opportunities in the field of psychiatry, neurology and pain at Janssen. From 1995 till 2011 she was a private professor at the VU University Medical Centre, Amsterdam, The Netherlands and held the title of Professor Brain Imaging and Receptor Pharmacology at the Department of Nuclear Medicine and PET Research.

Dr. Leysen has published over 230 peer reviewed full research papers and 66 reviews and book chapters. During her career she has been the recipient of several awards including the Johnson Medal for Research & Development (1998), Dr. Paul Janssen Award for Research (1993), Sterling Lecturer at the University of Pennsylvania (1992), Lundbeck-Prize for Research in Neuropsychopharmacology and Biological Psychiatry (1989).

Dr. Leysen was amongst the pioneers in receptor research and discovered and characterized the 5-HT2, later classified as 5-HT2A, receptor in the brain and peripheral tissues. Her 5HT2 receptor discovery and research formed the basis for the discovery of risperidone, the prototype of the second generation of so-called ‘atyptical’ antipsychotics. She led a team of scientists that contributed to the characterization of several neurotransmitter and neuropeptide receptors and the investigation of the mechanism of action and characterization of drugs that act on the central and peripheral nervous system. She is recognized as an outstanding expert in the field of receptor research and neuropsychopharmacology. Josée E. Leysen obtained maxima cum laude, the degrees of licentiate (Master) in Chemistry in 1968 and Doctor in Science, with specialty in Biochemistry and enzymology in 1972, at the University of Gent Belgium.”

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI; www.diabetesresearch.org) and the Cell Transplant Program. Dr. Ricordi also served as Responsible Head of the Human Cell Processing Facility (1993-2014), an NIH funded cGMP (current Good Manufacturing Practices) facility that has been providing Human Cell Products for research and clinical applications at UM, in Florida and worldwide since 1993. Dr. Ricordi has also served as Co-Director of the Executive Office of Research Leadership (2001-2003) as Senior Associate Dean for Research (2003-2006) and chaired the Dean’s Research Cabinet (2006-2012) at the UM Miller School of Medicine.

In 2015 Dr. Ricordi led the UM – UHealth – JMH team that performed the first successful transplant of a bioengineered endocrine pancreas implanted within a 3D bioactive resorbable scaffold in the abdominal cavity of a recipient with a severe form of Type 1 Diabetes (BioHUB Project). The patient has been able to discontinue insulin treatment since the first month post-transplant with excellent metabolic control. This unprecedented success resulted in renewed enthusiasm for the possibility to engineer this transplant site with additional strategies to avoid the requirements for recipient immunosuppression, and has resulted in additional key collaborative efforts, from Harvard to Stanford and with other leading international centers. The same year Dr. Ricordi launched the DRI Translational Fast Track Program to Reverse Autoimmunity and Induce Immune Tolerance, which he co-leads with Dr. Jay Skyler, in collaboration with several key UM investigators, from the SCCC, the DRI, the Departments of Medicine, Surgery, Biomedical Engineering, Microbiology and Immunology, Molecular and Cellular Pharmacology and Epidemiology.

Dr. Ricordi was president of the Cell Transplant Society (1992-94), co-founder and chairman of the National Diabetes Research Coalition (Chairman 1997), co-founder and president (1999-2001) of the International Association for Pancreas and Islet Transplantation (IPITA), and a member of the council of The Transplantation Society (2002-2008). He also served on the council of the American Society of Transplant Surgeons (2000-2002), on the National Institutes of Health (NIH-NIAID) Expert Panel on clinical approaches for tolerance induction, on the FDA Biologic Response Modifiers Advisory Committee, on the NIH/NCRR Islet Cell Resources (ICRs) Executive Committee, on the NIH-NIDDK Strategic Planning Committee and on the NIH-NIAID Expert Panel on Transplantation Research. He is currently serving as Chairperson of the Clinical Islet Transplant Consortium (NIDDK-NIAID). He has also been serving on several NIH study sections, including Surgery, Anesthesia and Trauma, the General Clinical Research Centers, Small Business Innovative Research, the Immune Tolerance Network, in addition to serving as a reviewer for several international funding agencies.

Dr. Ricordi has received numerous honors and awards, including the 2001 Nessim Habif World Prize in Surgery (University of Geneva) for developing a technology that significantly contributed to the advancement of a surgical field

Dr. Mulé is the Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in solid tumors. He has published nearly 200 articles in oncology, and holds domestic and international patents. Dr. Mulé serves on advisory boards of numerous biotechnology and pharma companies (e.g., Fulgent Diagnostics, OncoPep, Vault Pharma, Celgene, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific and Clinical Counselors.